BiotechTube

[18F]NAV4694

Phase 2UNKNOWN
0 watching 0 views this week⚡ Active
44
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Alzheimer Disease

Conditions

Alzheimer Disease

Trial Timeline

Aug 1, 2012 → Dec 1, 2018

NCT ID
NCT01680588

About [18F]NAV4694

[18F]NAV4694 is a phase 2 stage product being developed by Navidea Biopharmaceuticals for Alzheimer Disease. The current trial status is unknown. This product is registered under clinical trial identifier NCT01680588. Target conditions include Alzheimer Disease.

Hype Score Breakdown

Clinical
17
Activity
12
Company
2
Novelty
5
Community
5

Clinical Trials (3)

NCT IDPhaseStatus
NCT01886820Phase 3UNKNOWN
NCT01812213Phase 2Terminated
NCT01680588Phase 2UNKNOWN

Competing Products

20 competing products in Alzheimer Disease

See all competitors
ProductCompanyStageHype Score
Bromocriptine Mesilate + PlacebosTowa PharmaceuticalPhase 1/2
40
LY450139 + PlaceboEli LillyPhase 3
77
Solanezumab + PlaceboEli LillyPhase 3
77
LY450139 dihydrate + placeboEli LillyPhase 2
52
Zagotenemab + PlaceboEli LillyPhase 2
52
Donanemab + Placebo + LY3202626Eli LillyPhase 2
52
Donanemab + PlaceboEli LillyPhase 3
77
GSK4527226AlectorPhase 2
44
AL002 + PlaceboAlectorPhase 2
44
GSK4527226AlectorPhase 2
44
AL002AlectorPhase 2
44
Solanezumab + PlaceboEli LillyPhase 3
77
donanemabEli LillyPhase 2
52
ATH-1017LeonaBioPhase 2/3
57
ATH-1017 + PlaceboLeonaBioPhase 2/3
57
ATH-1017 + PlaceboLeonaBioPhase 2
44
NDX-1017 + PlaceboLeonaBioPhase 1
25
simufilamCassava SciencesPhase 2
44
50 mg PTI-125 + 100 mg PTI-125 + 200 mg PTI-125Cassava SciencesPhase 1
25
Placebo oral tablet + Simufilam 100 mg tablet + Simufilam 50 mg oral tabletCassava SciencesPhase 2
44

Other Products from Navidea Biopharmaceuticals

[18F]NAV4694Phase 3
69
LymphoseekPhase 3
69
LymphoseekPhase 3
69
NAV5001 + DaTscanPhase 3
69
NAV5001Phase 3
69